Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

hypertension

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

Roche chairman Franz Humer to step down

Will not stand for re-election in 2014

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Roche - Basel

Roche promises greater access to clinical trial data

Company critics say measures do not go far enough

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

Antitrust authorities in Italy open investigation into the pharma companies

Roche - Basel

Roche licenses Chiasma’s acromegaly drug in $595m deal

Alternative to injection for hormonal disorder

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

BMS hires Roche’s Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links